SPECIALTY GUIDELINE MANAGEMENT

NEULASTA (pegfilgrastim)
FULPHILA (pegfilgrastim-jmdp)
UDENYCA (pegfilgrastim-cbqv)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Neulasta
1. Patients with Cancer Receiving Myelosuppressive Chemotherapy
   Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
2. Hematopoietic Syndrome of Acute Radiation Syndrome
   Neulasta is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).

Fulphila
Patients with Cancer Receiving Myelosuppressive Chemotherapy
Fulphila is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Udenyca
Patients with Cancer Receiving Myelosuppressive Chemotherapy
Udenyca is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

B. Compendial Use

1. Stem cell transplantation-related indications
2. Prophylaxis for chemotherapy-induced febrile neutropenia in patients with solid tumors
3. Radiation therapy/injury
4. Hairy cell leukemia
5. Chronic Myeloid Leukemia (CML)

All other indications are considered experimental/investigational and are not a covered benefit.

II. REQUIRED DOCUMENTATION

A. Primary Prophylaxis of Febrile Neutropenia
1. Documentation must be provided of the member’s diagnosis and chemotherapeutic regimen.
2. If chemotherapeutic regimen has an intermediate risk of febrile neutropenia (10-19% [See Appendix B]), documentation must be provided outlining the patient’s risk factors that confirm the member is at high risk for febrile neutropenia.

III. CRITERIA FOR INITIAL APPROVAL

A. Prevention of neutropenia in cancer patients receiving myelosuppressive chemotherapy

Authorization of 6 months may be granted for prevention of febrile neutropenia when all of the following criteria are met (1, 2, 3, and 4):
1. The requested medication will not be used in combination with other colony stimulating factors within any chemotherapy cycle.
2. The member will not be receiving concurrent chemotherapy and radiation therapy.
3. The requested medication will not be administered with weekly chemotherapy regimens.
4. One of the following criteria is met (i or ii):
   i. The requested medication will be used for primary prophylaxis in members with a solid tumor or non-myeloid malignancies who have received, are currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of FN (See Appendix A) OR 10 – 19% risk of FN (See Appendix B) and who are considered to be at high risk of FN because of bone marrow compromise or co-morbidity, including any of the following (not an all-inclusive list):
      a. Active infections, open wounds, or recent surgery
      b. Age greater than or equal to 65 years
      c. Bone marrow involvement by tumor producing cytopenias
      d. Previous chemotherapy or radiation therapy
      e. Poor nutritional status
      f. Poor performance status
      g. Previous episodes of FN
      h. Other serious co-morbidities, including renal dysfunction, liver dysfunction, HIV infection, cardiovascular disease
      i. Persistent neutropenia
   ii. The requested medication will be used for secondary prophylaxis in members with solid tumors or non-myeloid malignancies who experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy, with the same dose and scheduled planned for the current cycle (for which primary prophylaxis was not received).

B. Other indications

Authorization of 6 months may be granted for members with any of the following indications:
1. Stem cell transplantation-related indications
2. Radiation therapy/injury
   i. Manage neutropenia in members acutely exposed to myelosuppressive doses of radiation therapy
   ii. Treatment of radiation injury
3. Hairy cell leukemia
   Individuals with hairy cell leukemia with neutropenic fever following chemotherapy.
4. Chronic Myeloid Leukemia
   Individuals with Chronic Myeloid Leukemia (CML) for treatment of resistant neutropenia due to tyrosine kinase inhibitor therapy

IV. CONTINUATION OF THERAPY
All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. APPENDIX

A. APPENDIX A: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 20% or Higher

1. Acute Lymphoblastic Leukemia:
   Select ALL regimens as directed by treatment protocol (see NCCN guidelines)

2. Bladder Cancer:
   i. Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)
   ii. CBDCa/Pac (carboplatin, paclitaxel)

3. Bone Cancer:
   i. VAI (vincristine, doxorubicin or dactinomycin, ifosfamide)
   ii. VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)
   iii. VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)

4. Breast Cancer:
   i. Docetaxel + trastuzumab
   ii. Dose-dense AC followed by T (doxorubicin, cyclophosphamide, paclitaxel)
   iii. TAC (docetaxel, doxorubicin, cyclophosphamide)
   iv. AT (doxorubicin, docetaxel)
   v. Doc (docetaxel)
   vi. TC (docetaxel, cyclophosphamide)
   vii. TCH (docetaxel, carboplatin, trastuzumab)

5. Esophageal and Gastric Cancers:
   Docetaxel/cisplatin/fluorouracil (5-FU)

6. Head and Neck Squamous Cell Carcinoma:
   TPF (docetaxel, cisplatin, fluorouracil [5-FU])

7. Hodgkin Lymphoma:
   i. Brentuximab vedotin + AVD (doxorubicin, vinblastine, dacarbazine)
   ii. Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)

8. Kidney Cancer:
   Doxorubicin/gemcitabine

9. Non-Hodgkin's Lymphoma:
   i. Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
   ii. ICE (ifosfamide, carboplatin, etoposide)
   iii. Dose-dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab
   iv. MINE (mesna, ifosfamide, novantrone, etoposide)
   v. DHAP (dexamethasone, cisplatin, cytarabine)
   vi. ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine (Ara-C))
   vii. HyperCVAD + rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone + rituximab)
   viii. VAPEC-B (vincristine, doxorubicin, prednisolone, etoposide, cyclophosphamide, bleomycin)

10. Melanoma:
    Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alpha)

11. Multiple Myeloma:
    i. DT-PACE (dexamethasone/thalidomide/cisplatin/ doxorubicin/cyclophosphamide/etoposide) + bortezomib (VTD-PACE)
ii. DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide)

12. Ovarian Cancer:
   i. Topotecan
   ii. Docetaxel

13. Soft Tissue Sarcoma:
   i. MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
   ii. Doxorubicin
   iii. Ifosfamide/doxorubicin

14. Small Cell Lung Cancer:
   i. Top (topotecan)
   ii. CAV (cyclophosphamide, doxorubicin, vincristine)

15. Testicular Cancer:
   i. VelP (vinblastine, ifosfamide, cisplatin)
   ii. VIP (etoposide, ifosfamide, cisplatin)
   iii. TIP (paclitaxel, ifosfamide, cisplatin)

B. APPENDIX B: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 19%

1. Occult Primary – Adenocarcinoma:
   Gemcitabine/docetaxel

2. Bone Cancer:
   i. Cisplatin/doxorubicin
   ii. VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)

3. Breast Cancer:
   i. Docetaxel
   ii. CMF classic (cyclophosphamide, methotrexate, fluorouracil [5-FU])
   iii. CA (doxorubicin, cyclophosphamide) (60 mg/m2) (hospitalized)
   iv. AC (doxorubicin, cyclophosphamide) + sequential docetaxel (taxane portion only)
   v. AC + sequential docetaxel + trastuzumab
   vi. A (doxorubicin) (75 mg/m2)
   vii. AC (doxorubicin, cyclophosphamide)
   viii. CapDoc (capecitabine, docetaxel)
   ix. Paclitaxel every 21 days

4. Cervical Cancer:
   i. Irinotecan
   ii. Cisplatin/topotecan
   iii. Paclitaxel/cisplatin
   iv. Topotecan

5. Colorectal Cancer:
   i. FL (fluorouracil [5-FU], leucovorin)
   ii. CPT-11 (irinotecan) (350 mg/m2 q 3 wk)
   iii. FOLFOX (fluorouracil [5-FU], leucovorin, oxaliplatin)

6. Esophageal and Gastric Cancers:
   i. Irinotecan/cisplatin
   ii. Epirubicin/cisplatin/fluorouracil (5-FU)
   iii. Epirubicin/cisplatin/capecitabine

7. Head and Neck Cancers:
   Cis/Doc/5-FU (cisplatin, docetaxel, fluorouracil [5-FU])

8. Non-Hodgkin’s Lymphoma:
   i. EPOCH-IT chemotherapy
   ii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin)
iii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin) + rituximab  
iv. FMR (fludarabine, mitoxantrone, rituximab)  
v. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) including regimens with pegylated liposomal doxorubicin  
vi. CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin

9. Non-Small Cell Lung Cancer:  
i. Cisplatin/paclitaxel  
ii. Cisplatin/vinorelbine  
iii. Cisplatin/docetaxel  
iv. Cisplatin/etoposide  
v. Carboplatin/paclitaxel  
vi. Docetaxel

10. Ovarian Cancer:  
Carboplatin/docetaxel

11. Pancreatic Cancer:  
FOLFiRiNOX (folinic acid [leucovorin], fluorouracil [5-FU], irinotecan and oxaliplatin)

12. Prostate Cancer:  
Cabazitaxel

13. Small Cell Lung Cancer:  
Etoposide/carboplatin

14. Testicular Cancer:  
i. BEP (bleomycin, etoposide, cisplatin)  
ii. Etoposide/cisplatin

15. Uterine Sarcoma:  
Docetaxel

V. REFERENCES